Herb-Drug Interaction & Safety Screening Note

Herb-Drug Interaction & Safety Screening Note

Date/Time: [Date and time of documentation]

Author: [Author name and credentials]

Encounter Type: [in-person / telehealth / chart review]

Referral Source: [Referring clinician or service / self-referred / not applicable]

Reason for Screening

[Brief statement of why screening is performed today, including target supplement(s) and/or medication(s) prompting review] (1–3 sentences. State purpose: pre-initiation clearance, ongoing safety monitoring, adverse event evaluation, or peri-procedural risk review.)

Data Sources & Reconciliation Status

• Medication sources reviewed: [EHR medication list / patient report / external pharmacy records / anticoagulation clinic list / other]
• Supplement sources reviewed: [Patient report / label or bottle verified / photo of product provided / other]
• Reconciliation status: [Reconciled / partially reconciled / not reconciled] — [Explanation of status and any discrepancies; for supplements, state whether verified by label/photo or unverified (patient recall only); specify unknown fields with planned follow-up]

Current Medications

(List prescription and OTC medications. For PRN medications, include typical frequency. Flag high-risk categories within each line item.)

• [Medication name (generic)] — [dose, route, frequency] — [indication] — [High-risk flag if applicable: anticoagulant / antiplatelet / NSAID / narrow therapeutic index / none]
• (Repeat for additional medications.)

(If none, write: "No current medications reported.")

Current Supplements / Herbals / Botanicals

(For each product, record details as available. If label not available, state unknown fields explicitly without inferring identity.)

• [Product name as on label] — [Common name; Latin binomial if known] — [dose/strength] — [frequency] — [formulation: capsule / tablet / tea / tincture / powder / other] — [start date] — [patient's stated reason for use] — [single-ingredient / multi-ingredient]
  Verification: [Label/photo verified / patient recall only] (Note any unknown fields.)
• (Repeat for additional supplements.)

(If none, write: "Patient reports no herbals or dietary supplements at this time.")

Risk Factor Screen

(Document each domain as Yes/No/Unknown/Not assessed. Elaborate when positive or when unknown status is clinically relevant.)

• Pregnancy/Lactation: [Yes / No / Unknown / Not assessed] — [Pregnancy status, lactation status, trying to conceive]
• Hepatic: [Yes / No / Unknown / Not assessed] — [Liver disease history, prior supplement-induced liver injury, hepatotoxic co-exposures, recent LFTs if pertinent]
• Renal: [Yes / No / Unknown / Not assessed] — [CKD stage/eGFR, dialysis status, nephrotoxic co-exposures]
• Bleeding/Thrombosis: [Yes / No / Unknown / Not assessed] — [Anticoagulant/antiplatelet use, bleeding history, planned procedures, recent INR if on warfarin]
• Other high-risk contexts: [Yes / No / Unknown / Not assessed] — [Transplant/immunosuppression, oncology therapy, HIV therapy, seizure medications, serotonergic psychiatric medications, pediatric or frail elderly status, relevant allergies including botanical family cross-reactivity]

Interaction Screening Results

Screening resources used: [Databases, references, and institutional tools consulted with date] (Include limitations statement if relevant, e.g., unverified supplement identity.)

High-risk interaction summary: (List up to 5 most clinically significant interactions, prioritized by potential harm and time sensitivity.)

• [Top risk: concise description of supplement–drug or supplement–condition concern]
• (Add additional items as applicable.)

(If no major interactions identified, write: "No clinically significant interactions identified using listed sources; evidence limitations reviewed with patient.")

Interaction Details

(Document each clinically relevant supplement–drug or supplement–condition pair.)

• [Supplement/ingredient] – [Interacting medication or condition]
  • Interaction type: [Pharmacokinetic / pharmacodynamic / additive toxicity / lab interference / peri-procedural]
  • Clinical concern: [Brief plain-language description of potential effect]
  • Severity: [Avoid / Use with caution / Monitor / Minimal or none known]
  • Evidence strength: [Strong / Moderate / Limited] — [Study type: clinical trial / observational / case report / in vitro / animal]
  • Recommended action: [Actionable recommendation tailored to patient context]
  • Communication needed: [Notify anticoagulation clinic / message prescriber / inform procedural team / none]
• (Repeat for additional interactions.)

Contraindications/Precautions

(Document applicable precautions. Omit categories that do not apply.)

• [Pregnancy/lactation-related cautions]
• [Hepatic cautions]
• [Renal cautions]
• [Perioperative concerns]
• [Other condition-specific precautions]

Clinical Interpretation

[Narrative synthesis of risks and benefits] (1–2 short paragraphs addressing: patient's goals for supplement use, whether safer alternatives exist, risk-benefit framing tailored to patient context, and explicit statement of what is known vs suspected vs unknown. Use hedged language unless strong evidence supports causal statements. If supplement identity is uncertain, state that risk assessment is provisional.)

Plan

• Supplement actions: [For each supplement: continue / stop / hold pending more info / change product / avoid future use — with rationale]
• Medication implications: [Recommended medication changes and responsible clinician, or "None indicated"] (Do not imply changes occurred unless ordered.)
• Monitoring: [What to monitor: symptoms/labs] — [Timeframe] — [Responsible clinician/service]
• Follow-up: [When and with whom]
• Care coordination: [Interprofessional communications sent: messages, calls, referrals]

(If plan depends on missing details, write: "Plan deferred pending [specific information needed]" with concrete next step.)

Patient Counseling

• [Encouraged disclosure of all supplements/OTCs to all clinicians]
• [Discussed product variability, contamination risk, and/or multi-ingredient complexity as relevant]
• [Specific stop/hold instructions provided for supplements; reinforced not to stop prescribed medications without clinician direction]
• [Seek-care symptoms reviewed, tailored to identified risks]
• Teach-back: [Patient verbalized understanding / misunderstanding noted and corrected]

Adverse Event Assessment

[No adverse event reported; screening performed for prevention.]

(If adverse event suspected, document the following:)

• Event description: [Symptoms/signs]
• Onset timeline: [Start date/time, relation to exposures]
• Suspect products: [Product/brand/lot if available, dose/formulation]
• Co-exposures: [Medications/other supplements/OTCs]
• Objective findings: [Vitals, exam, pertinent labs/imaging]
• Actions taken: [Product stopped/held / dose changed / labs ordered / referral / supportive care]
• Seriousness indicators: [Hospitalization / disability / life-threatening / required intervention / none]
• Safety reporting: [Discussed/initiated report to appropriate agency / not indicated]

References

• [Interaction databases/resources consulted with dates]
• [Institutional guidelines or policies referenced]
• [Specialty safety resources used]